Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Yuhong Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5710-9096; OpenAlex author ID A5100341165. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 trial · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Mortality from sepsis among middle-aged and elderly patients with pancreatic cancer: CDC WONDER 1999 To 2023. Co-author DOI 10.3389/fonc.2025.1696866↗
  2. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.12.008↗
  3. A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.intimp.2021.107890↗
  4. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Last author DOI 10.1186/s40880-019-0367-7↗
  5. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. Co-author DOI 10.7150/jca.14185↗
  6. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00280-013-2102-4↗
  7. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. Co-author DOI 10.1186/1479-5876-11-249↗
  8. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Co-author DOI 10.1002/ijc.26376↗

Trials 1

  1. Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. Principal investigator NCT04224402↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng‐Hua Wang · 5 shared papers, 2012–2024 · strength 0.39
  2. Miao‐Zhen Qiu · 5 shared papers, 2012–2024 · strength 0.34
  3. A Guan · 1 shared paper, 2025 · strength 0.27
  4. Peng Yao · 1 shared paper, 2025 · strength 0.27
  5. Rui‐Hua Xu · 5 shared papers, 2012–2019 · strength 0.23
  6. De‐Shen Wang · 4 shared papers, 2012–2019 · strength 0.20
  7. Xujia Li · 1 shared paper, 2024 · strength 0.20
  8. Shengping Li · 1 shared paper, 2024 · strength 0.20
  9. Guifang Guo · 1 shared paper, 2024 · strength 0.20
  10. Qi Quan · 1 shared paper, 2024 · strength 0.20
  11. Zhigang Chen · 1 shared paper, 2021 · strength 0.15
  12. Yun Wang · 1 shared paper, 2021 · strength 0.15
  13. Zhi‐Qiang Wang · 2 shared papers, 2012–2019 · strength 0.12
  14. Ting Deng · 1 shared paper, 2019 · strength 0.09
  15. Fei Zhang · 1 shared paper, 2019 · strength 0.09
  16. Le Zhang · 1 shared paper, 2019 · strength 0.09
  17. Wei Wang · 1 shared paper, 2019 · strength 0.09
  18. Yi Ba · 1 shared paper, 2019 · strength 0.09
  19. Dongsheng Zhang · 2 shared papers, 2012–2016 · strength 0.08
  20. Dong-sheng Zhang · 2 shared papers, 2013 · strength 0.07
  21. Feng Wang · 1 shared paper, 2016 · strength 0.05
  22. Xiaoli Wei · 1 shared paper, 2013 · strength 0.03
  23. Feng Wang · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.